Editas Medicine Inc. Common Stock (EDIT)

FairStock Score: 33/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with durable earnings and a margin of safety. Editas has neither today. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $11.9 million and net income was -$18.2 million, or -$0.15 per diluted share. For fiscal year 2025, the period ended 2025-12-31, revenue was $40.5 million and net loss was $160.1 million, or -$1.80 per diluted share. Revenue did improve from $3.6 million in fiscal Q2 2025, the quarter ended 2025-06-30, but the company remains deeply unprofitable. Trailing free cash flow was -$120.5 million, a -32.1% FCF yield against the $375.5 million market cap at the 2026-10-13 close. FairStock calculations show a -3.70 P/E, 3.54 P/B, -118.82% ROE, -23.29% ROCE, Piotroski 3/9, Altman Z -7.62, and no Peter Lynch category because it lost money in each of the last four years. FairStock scores it 33/100. Low debt, with D/E of 0.15, helps, but clinical pipelines consume cash. The CRISPR platform and lead EDIT-401 program could become valuable if approved, but I cannot quantify a moat or normalize earnings from today's statements. At $2.44, within a 52-week range of $1.66-$4.33, the market is paying for future optionality rather than present fundamentals. To me, this is speculation, not a Graham bargain.

In plain English: Editas Medicine is a small experimental biotech that uses gene editing to try to make one-time treatments, including for high cholesterol. It is not profitable and is spending more cash than it brings in, though its latest quarterly revenue was higher than a year earlier. At $2.44, the price looks expensive compared with today's sales and profits because the value depends on future treatments that may or may not work.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer